HEMANGEOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8987262 | PIERRE FABRE DERMA | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(4 years from now) | |
| US8338489 | PIERRE FABRE DERMA | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(4 years from now) | |
Hemangeol is owned by Pierre Fabre Derma.
Hemangeol contains Propranolol Hydrochloride.
Hemangeol has a total of 2 drug patents out of which 0 drug patents have expired.
Hemangeol was authorised for market use on 14 March, 2014.
Hemangeol is available in solution;oral dosage forms.
Hemangeol can be used as method to treat hemangioma., method to treat infantile hemangioma.
The generics of Hemangeol are possible to be released after 16 October, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 14, 2021 |
| New Product(NP) | Mar 14, 2017 |
| Orphan Drug Exclusivity(ODE-62) | Mar 14, 2021 |
Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 March, 2014
Treatment: Method to treat infantile hemangioma; Method to treat hemangioma.
Dosage: SOLUTION;ORAL
How can I launch a generic of HEMANGEOL before it's drug patent expiration?
More Information on Dosage
HEMANGEOL family patents
